SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Oral, H.
Right arrow Articles by Morady, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Oral, H.
Right arrow Articles by Morady, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment

Hakan Oral

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Bradley P. Knight

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Christian Sticherling

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Michael H. Kim

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Robert L. Baker

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Steven P. Chough

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Kristina Wasmer

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Frank Pelosi, JR

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Gregory F. Michaud

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

A. Mark Fendrick

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

S. Adam Strickberger

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Fred Morady

Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI

Background: Ibutilide may result in chemical cardioversion of atrial fibrillation and facilitates transthoracic cardioversion by lowering the defibrillation energy requirement. Whether routine pretreatment with ibutilide increases or decreases the cost of cardioversion is unknown. The purpose of this study was to compare the cost of outpatient transthoracic cardioversion of atrial fibrillation with and without ibutilide pretreatment.

Methods: Using a model based on published literature and hospital accounting information, a hypothetical group of 100 patients with atrial fibrillation and a left ventricular ejection fraction >0.30 underwent 2 strategies of outpatient cardioversion: transthoracic cardioversion with and without routine pretreatment with 1 mg ibutilide, and with and without involvement of an anesthesiologist for sedation. If transthoracic cardioversion was unsuccessful in patients who did not receive ibutilide, transthoracic cardioversion was repeated after administration of ibutilide.

Results: If an anesthesiologist was involved, transthoracic cardioversion with ibutilide was associated with incremental cost-savings as the efficacy of ibutilide alone in restoring sinus rhythm increased above the critical values of 20%, 27%, and 35% when the efficacy of transthoracic cardioversion alone was 60%, 80%, and 100%, respectively. In the absence of an anesthesiologist, routine pretreatment with ibutilide increased the cost of cardioversion at all success rates of transthoracic cardioversion.

Conclusions: In the presence of an anesthesiologist, whether or not routine pretreatment with ibutilide lowers the mean cost of cardioversion is determined by the success rates of chemical cardioversion with ibutilide and transthoracic cardioversion. In the absence of an anesthesiologist, ibutilide pretreatment increases the cost of cardioversion.

Key Words: atrial fibrillation • cardioversion • ibutilide.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 5, No. 4, 259-266 (2000)
DOI: 10.1054/JCPT.2000.16696


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement